Premier Research
Premier Research is recorded as a service provider in 79 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 79 trials · Latest update first
A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Study to Assess the Safety of ELGN-2112 in Populations of Interest
Sponsor Elgan Pharma Ltd.
- Start (EU)
- Latest update
- Estimated end
C6231002 - A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF 08049820 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Open-label, Phase 1/2, Dose-escalation and Subsequent Safety Extension Study of Subcutaneous KK8123 in Adult Patients with X-linked Hypophosphatemia
Sponsor Kyowa Kirin Inc.
- Start (EU)
- Latest update
- Estimated end
C4221016 - A Phase 3, Randomized, Double-Blind Study of Encorafenib and Binimetinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants with BRAF V600E/K Mutation-Positive Metastatic or Unresectable Locally Advanced Melanoma
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
A Global, Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety and Tolerability of NBI-1117568 in Adults with Schizophrenia
Sponsor Neurocrine Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
BEACON2: A multi-arm multi-stage platform trial for relapsed neuroblastoma
Sponsor The University Of Birmingham
- Start (EU)
- Latest update
- Estimated end
A PHASE 3, EXTERNAL AND SYNTHETIC PLACEBO-CONTROLLED RANDOMIZED STUDY WITH DOSE-UP FOR NON-RESPONDERS TO INVESTIGATE SAFETY AND EFFICACY OF RITLECITINIB 50 MG AND 100 MG ONCE DAILY IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH ALOPECIA AREATA
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
A Global, Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1117568 in Adults with Schizophrenia Who Warrant Inpatient Hospitalization
Sponsor Neurocrine Biosciences Inc.
- Start (EU)
- Latest update
- Estimated end
Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Hypochondroplasia: ACCEL OLE
Sponsor Qed Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Open-label safety and efficacy trial of chlorhexidine and/or metronidazole pre-treatment followed by FB301 in women with bacterial vaginosis (BV)
Sponsor Freya Biosciences ApS
- Start (EU)
- Latest update
- Estimated end
- Not reported
A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Study to Evaluate Efficacy of Roluperidone on Negative Symptoms in Adult Subjects with Schizophrenia, Followed by a 40-Week, Randomized, Double-Dummy Phase to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
Sponsor Minerva Neurosciences Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Monotherapy Study of the Efficacy, Safety, and Tolerability of SPT-300 in Adults with Major Depressive Disorder (MDD), with or without Anxious Distress
Sponsor Seaport Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of ORKA-001 in Participants with Moderate-to-Severe Plaque Psoriasis
Sponsor Oruka Therapeutics Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (subcutaneous use) in Patients with Primary Hyperoxaluria
Sponsor Dicerna Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Preceded by a Single Ascending Dose Portion and a Phase 2 Open-Label Portion, to Evaluate the Safety and Efficacy of Oral Infigratinib in Infants and Young Children with Achondroplasia
Sponsor Qed Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A phase 3, randomised, 2-arm, parallel-group, double-blind, placebo-controlled trial to evaluate the efficacy and safety of subcutaneous methotrexate versus placebo in moderate to severe atopic dermatitis
Sponsor Medac Gesellschaft fuer klinische Spezialprapaerate mbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
C4921003 - A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Oral Branched-Chain Ketoacid Dehydrogenase Kinase Inhibitor, PF-07328948 in Adults with Heart Failure (BRANCH-HF)
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
C3651021: A PHASE 2b/3, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PONSEGROMAB (PF-06946860) COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRST-LINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
C0251010 - A Phase 3, Multi-center, Open-label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Dazukibart in Participants with Idiopathic Inflammatory Myopathies (Including Participants with Dermatomyositis or Polymyositis)
Sponsor Pfizer Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-Label Study to Assess the Long-Term Safety and Tolerability of ML-007C-MA in Adult Participants with Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
Sponsor Maplight Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Premier Research?
The 2026-10-09 snapshot links Premier Research to 79 distinct CTIS trials. Recorded services include Clinical monitoring, Data management, Regulatory services, Project management, among 31 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Premier Research?
The most frequently recorded therapeutic areas are Dermatology, Genetic and Congenital Disorders, Psychiatry, Immunology. Recorded phases include Phase 2, Phase 3, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Premier Research conducted?
The linked trials record locations in 22 countries, including Spain, Germany, France, Italy, Poland. These are trial locations, not confirmed office locations or countries where Premier Research delivered services.
What can this page tell me about Premier Research's trial experience?
Browse 79 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 8 recorded name variants under Premier Research. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Premier Research
- Premier Research GmbH
- Premier Research Group Limited
- Premier Research Group S.L.
- Premier Research International LLC
- Premier Research Poland Sp. z o.o.
- Premier Research Romania S.R.L.
- Premier Research s.r.o.